openPR Logo
Press release

Discover the Growth of the Hepatitis A Vaccines Market

01-18-2018 02:05 PM CET | Health & Medicine

Press release from: Transparency Market Research

Hepatitis A is a liver disease caused by hepatitis A virus that can lead to mild to severe illness. The hepatitis A virus (HAV) is spread through direct contact with an infectious person or through ingestion of contaminated food and water. Most patients recover fully from hepatitis A with a lifelong immunity. However, a small number of people with hepatitis A could succumb to the disease.

Rise of hepatitis A infection is linked with poor sanitation & hygiene and lack of safe water. Hepatitis A occurs periodically and in epidemics globally, with a propensity for cyclic reappearances. The hepatitis A virus is one of the common reasons for foodborne infection. An effective and safe vaccine is available to prevent hepatitis A. Safe water supply, food safety, improved sanitation, and hand washing could also be effective ways to combat hepatitis A.

According to the U.S. Department of Health and Human Services, hepatitis A is a vaccine-preventable, communicable disease of the liver caused by the hepatitis A virus (HAV). Antibodies produced in response to hepatitis A infection last through life and protect against recurrence of infection. The best way to prevent hepatitis A is through vaccination. Vaccines available in market are Havrix, Vaqta, and Twinrix. Vaccination is recommended for all children aged 12 months or older, travelers to locations with increased hepatitis A infection, people who inject illegal drugs, those with a blood clotting problem, and anyone with long-term liver disease.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37664

Hepatitis A vaccine is given in two doses, six months apart. The vaccine also comes in a combination form, containing both hepatitis A and B vaccine, which can be given to persons 18 years or older. This form is given as three doses, over a period of six months or as three doses over one month and a booster dose at 12 months. A dose called immune globulin (IG) can be considered an addition to hepatitis A vaccine for adults, persons with compromised immunity, and persons with chronic liver disease or other chronic medical conditions who are traveling within two weeks.

Based on distribution channel, the global hepatitis A vaccines market can be segmented into hospitals, clinics, and organizations associated with government vaccinations programs. Rise in number of hepatitis A cases is forcing governments and health care organizations to spread awareness about the disease. This drives the global hepatitis A vaccines market. According to the Centers for Disease Control and Prevention, in 2015, a total of 1,390 cases of hepatitis A were reported from 50 states in the U.S. The overall incidence rate in 2015 was 0.4 cases per 100,000 population. Actual acute cases are estimated to be 1.96 times the number of reported cases in any year.

The global hepatitis A vaccines market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is projected to reflect a high CAGR due to rise in pediatric population and increase in awareness about vaccination. Continuous efforts by market players and national organizations to promote hepatitis A vaccines is likely to drive the market in the developed regions.

According to the WHO, in developing countries with poor sanitary conditions and hygienic practices, around 90.0% children are infected with the hepatitis A virus before the age of 10 years. Government vaccination programs in developing countries propel the global hepatitis A vaccines market. Rise in awareness about hepatitis is also one of the key factors augmenting the market in developing countries.

Pre-Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=37664<ype=S

Key players in the global hepatitis A vaccines market include GlaxoSmithKline and Merck & Co., Inc.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Discover the Growth of the Hepatitis A Vaccines Market here

News-ID: 907345 • Views:

More Releases from Transparency Market Research

Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights for the USD 15.9 Bn Market 2022-2031
Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights f …
The global handheld marijuana vaporizer market has witnessed remarkable growth in recent years, attributed to the increasing acceptance of medicinal marijuana and the demand for convenient and discreet consumption methods. Valued at US$ 5 billion in 2021, the market is projected to surge at a CAGR of 13.4% to reach US$ 15.9 billion by 2031. This article delves into the factors driving this growth, the evolving market landscape, and the
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And Competitors
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And …
The COVID-19 pandemic has precipitated a remarkable surge in the demand for disinfectant products, with a notable emphasis on disinfectant wipes as an essential tool in maintaining hygiene and preventing the spread of pathogens. This research report delves into the multifaceted landscape of the disinfectant wipes market, elucidating key trends, drivers, and innovations shaping the industry. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=70359 Key Players and Market Developments Key players
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn

All 5 Releases


More Releases for Hepatitis

Is Hepatitis A Vaccine Required?
Hepatitis A Vaccine Market describes its growth, size, share, Forecast and trends to 2025 Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available
Hepatitis Drugs Market Is Growing Due to Increasing R&D Investments on Hepatitis …
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest
Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B In …
Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and
Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth
Global Hepatitis E Diagnostic Tests Market: Snapshot The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. There is increasing prevalence of hepatitis E in resource-limited region, such as various countries of Asia Pacific. The people of these regions suffer with frequent water contamination and have limited access to sanitation and hygiene,
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each